Panelists discuss how integrating subcutaneous (SubQ) therapies into oncology practice involves thorough economic evaluation, coordinated team education, patient engagement, and workflow adjustments ...

Spain: Researchers have found in a real-world cohort of patients with giant cell arteritis–associated aortitis, published in ...

MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...

Panelists discuss how the shift from intravenous (IV) to subcutaneous (SubQ) drug administration is transforming oncology care delivery, highlighting its lasting impact on patient experience, health ...

Subcutaneous Opdivo showed similar efficacy and safety to intravenous Opdivo in advanced ccRCC, with a slightly higher overall response rate. The CheckMate-67T trial confirmed pharmacokinetic and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. At week 48, 58.7% of guselkumab IV induction ...

Please provide your email address to receive an email when new articles are posted on . Nearly 90% of patients with relapsing-remitting MS in a multicenter study in Germany preferred subcutaneous ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window CHICAGO -- ...

Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) said a subcutaneous (under the skin) formulation of Tecentriq showed to be as good as an intravenous (IV) infusion of the drug in a study consisting of ...

A phase 3 trial demonstrated shorter administration times with subcutaneous vs IV delivery of nivolumab with no significant difference in mRCC progression-free survival. Subcutaneous administration of ...